12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fulranumab regulatory update

FDA's Arthritis Drugs Advisory Committee voted 21-0 that anti- nerve growth factor (NGF) agents should continue to be developed to treat osteoarthritis (OA) pain. Because the joint destruction was increased in patients taking anti-NGFs with NSAIDs, the panel felt studies in OA could continue if concomitant NSAID use is excluded and additional safeguards are put in place. These could include measuring biomarkers of joint destruction and increasing use of MRI. The panel did not feel anti-NGFs should be...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >